Oric Pharmaceuticals Reports Enozertinib Phase 1b Results, Plans Phase 3 in 2027

Oric Pharmaceuticals reported Phase 1b results for enozertinib, showing 84% systemic and 70% intracranial response rates. The drug was well tolerated. The company plans a global Phase 3 trial, Redwood-1, in 2027, aiming to enroll 360 patients. According to the company, the trial will have dual primary endpoints of ORR and PFS.

Original reporting
Published Oct 23, 2026, 12:03 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 23, 2026, 12:15 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Oric Pharmaceuticals Reports Enozertinib Phase 1b Results, Plans Phase 3 in 2027 — source image
Decision brief

The 30-second read

$ORICBullishMed
01

Why it matters

The data could catalyze a price rally, but investors should monitor enrollment and safety signals in the upcoming trial.

02

Market read

First disclosure of promising trial data for a small‑cap biotech, likely to move the stock.

03

What to watch

Potential competition from other EGFR inhibitors and regulatory timelines.

Relevance 8/10Novelty 8/10Timing: today

Background

Oric filed an 8‑K reporting its Phase 1b enozertinib data and future Phase 3 plans.

Company-level read

Ticker impact

$ORICBullishHigh confidence
Context

Oric Pharmaceuticals disclosed Phase 1b data showing 84% systemic ORR and 70% intracranial ORR for enozertinib, and announced a Phase 3 trial for 2027.

Expected impact

upward pressure as investors price in the high response rates and upcoming Phase 3 trial.

Evidence & confidence

Phase 1b data with high ORR is material for a biotech; market typically reacts positively to such efficacy signals.

Market effects

May boost sentiment for other EGFR‑targeted oncology firms.

Limited to US biotech sector.

Modest, primarily relevant to investors tracking early‑stage cancer therapeutics.

Counterpoint

Phase 1b success does not guarantee Phase 3 outcomes; risk of later‑stage failure remains.

Key entities

  • Oric Pharmaceuticals

    US‑listed biotech developing enozertinib for brain metastases.

Related articles

$ORICMed

Wedbush reiterates Oric Pharmaceuticals stock rating on trial data

Wedbush reiterated an Outperform rating and $14.00 price target for ORIC Pharmaceuticals (ORIC) after its Q3 2026 earnings update. The stock is near its 52-week low at $7.52. InvestingPro values ORIC at $8.57. The company shared positive trial data for rinzimetostat in prostate cancer, with Phase 3 studies ongoing. BTIG and Stifel also issued Buy ratings with higher price targets.

$ORICMedAI 8/10

ORIC® Pharmaceuticals Reports Third Quarter 2026 Financial Results and Provides Operational and Rinzimetostat Program Updates

Oric Pharmaceuticals, Inc. (ORIC) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 ORIC ® Pharmaceuticals Reports Third Quarter 2026 Financial Results and Provides Operational and Rinzimetostat Program Updates Initiated Himalayas-1 global Phase 3 trial in patients with mCRPC previously treated with abiraterone, supported by a clinical trial collabo